Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
5.01
0.00 (0.00%)
At close: Apr 1, 2026, 4:00 PM EDT
5.01
0.00 (0.00%)
After-hours: Apr 1, 2026, 4:00 PM EDT
Lisata Therapeutics Employees
Lisata Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 5 or -19.23% compared to the previous year.
Employees
21
Change (1Y)
-5
Growth (1Y)
-19.23%
Revenue / Employee
$8,095
Profits / Employee
-$789,810
Market Cap
45.25M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21 | -5 | -19.23% |
| Dec 31, 2024 | 26 | 1 | 4.00% |
| Dec 31, 2023 | 25 | -2 | -7.41% |
| Dec 31, 2022 | 27 | 0 | - |
| Dec 31, 2021 | 27 | 3 | 12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Werewolf Therapeutics | 39 |
| Sensei Biotherapeutics | 15 |
| Atossa Therapeutics | 15 |
| Rallybio | 14 |
| Nutriband | 13 |
| RenovoRx | 10 |
| Telomir Pharmaceuticals | 9 |
| NovaBay Pharmaceuticals | 4 |
LSTA News
- 25 days ago - Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewsWire
- 2 months ago - Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - GlobeNewsWire
- 2 months ago - Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - GlobeNewsWire
- 5 months ago - Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year' - GlobeNewsWire
- 5 months ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 5 months ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire
- 6 months ago - Lisata Therapeutics to Present at LD Micro Main Event XIX - Newsfile Corp